Reporting of all cardiac medications and their outcome in COVID-19.
作者信息
Mishra Ajay K, Sahu Kamal K, Lal Amos
机构信息
Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts.
Division of Critical Care and Pulmonary Medicine, Mayo Clinic, Rochester, Minnesota.
出版信息
J Med Virol. 2020 Sep;92(9):1419-1420. doi: 10.1002/jmv.25843. Epub 2020 Jun 9.
Abstract
摘要
相似文献
1
Reporting of all cardiac medications and their outcome in COVID-19.报告所有心脏药物及其在新冠病毒疾病（COVID-19）中的疗效。
J Med Virol. 2020 Sep;92(9):1419-1420. doi: 10.1002/jmv.25843. Epub 2020 Jun 9.
2
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.假说：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能会增加 COVID-19 重症风险。
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
3
COVID-19: The heart of the issue.新冠病毒：问题的核心。
J Card Surg. 2020 Aug;35(8):2112. doi: 10.1111/jocs.14684. Epub 2020 Jun 16.
4
COVID-19 and obesity: links and risks.2019冠状病毒病与肥胖：关联及风险
Expert Rev Endocrinol Metab. 2020 Jul;15(4):215-216. doi: 10.1080/17446651.2020.1767589. Epub 2020 May 22.
5
Cardiovascular disease and the impact of COVID-19.心血管疾病与2019冠状病毒病的影响
J Card Surg. 2020 Aug;35(8):2113. doi: 10.1111/jocs.14682. Epub 2020 Jun 16.
6
COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?新型冠状病毒肺炎与肾素-血管紧张素系统抑制：血管紧张素转换酶 2（ACE2）的作用-争议有何科学依据？
J Intern Med. 2020 Oct;288(4):410-421. doi: 10.1111/joim.13101. Epub 2020 Jun 8.
7
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报2：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Sep 1;173(5):W87. doi: 10.7326/L20-0969. Epub 2020 Jul 23.
8
Reply to: "Reporting of all cardiac medications and their outcome in COVID-19".回复：“关于COVID-19中所有心脏药物及其疗效的报告”。
J Med Virol. 2020 Sep;92(9):1421-1422. doi: 10.1002/jmv.25868. Epub 2020 Jun 3.
9
At High Altitude COVID-19 Is Less Frequent: The Experience of Peru.在高海拔地区，新冠病毒感染率较低：秘鲁的经验。
Arch Bronconeumol (Engl Ed). 2020 Nov;56(11):760-761. doi: 10.1016/j.arbres.2020.06.015. Epub 2020 Jul 16.
10
COVID-19 challenging cell biology.新冠病毒对细胞生物学构成挑战。
Protoplasma. 2020 May;257(3):619-620. doi: 10.1007/s00709-020-01506-z. Epub 2020 Apr 24.
引用本文的文献
1
Mechanism and potential treatments for gastrointestinal dysfunction in patients with COVID-19.新型冠状病毒肺炎患者胃肠功能障碍的发病机制及潜在治疗方法。
World J Gastroenterol. 2022 Dec 28;28(48):6811-6826. doi: 10.3748/wjg.v28.i48.6811.
2
Infective endocarditis and COVID -19 coinfection: An updated review.感染性心内膜炎与 COVID-19 合并感染：最新综述。
Acta Biomed. 2022 Mar 14;93(1):e2022030. doi: 10.23750/abm.v93i1.10982.
3
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.评估在重症 COVID-19 患者的治疗中添加伊维菌素的有效性和安全性。
BMC Infect Dis. 2021 May 4;21(1):411. doi: 10.1186/s12879-021-06104-9.
4
An Update on Pulmonary Hypertension in Coronavirus Disease-19 (COVID-19).新型冠状病毒肺炎相关肺动脉高压的研究进展。
Acta Biomed. 2020 Nov 10;91(4):e2020155. doi: 10.23750/abm.v91i4.10698.
5
Current Perspectives of convalescent plasma therapy in COVID-19.COVID-19 恢复期血浆疗法的现状。
Acta Biomed. 2020 Nov 10;91(4):e2020175. doi: 10.23750/abm.v91i4.10681.
6
Electrocardiographic Findings and Clinical Outcome in Patients with COVID-19 or Other Acute Infectious Respiratory Diseases.新型冠状病毒肺炎或其他急性感染性呼吸道疾病患者的心电图表现及临床结局
J Clin Med. 2020 Nov 12;9(11):3647. doi: 10.3390/jcm9113647.
7
Trajectory of the COVID-19 pandemic: chasing a moving target.新冠疫情的轨迹：追逐一个移动的目标。
Ann Transl Med. 2020 Jun;8(11):694. doi: 10.21037/atm-20-2793.
8
A review of cardiac manifestations and predictors of outcome in patients with COVID - 19.COVID-19 患者的心脏表现和预后预测因素综述。
Heart Lung. 2020 Nov-Dec;49(6):848-852. doi: 10.1016/j.hrtlng.2020.04.019. Epub 2020 May 3.
9
Letter to the Editor Regarding "Acute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic: From Trough of Disillusionment to Slope of Enlightenment".致编辑的信：关于“2019年冠状病毒病（COVID-19）大流行期间的急性卒中管理：从幻想破灭的低谷到渐入佳境的斜坡”
World Neurosurg. 2020 Oct;142:551-552. doi: 10.1016/j.wneu.2020.06.111. Epub 2020 Jun 24.
10
India Fights Back: COVID-19 Pandemic.印度反击：新冠疫情
Heart Lung. 2020 Sep-Oct;49(5):446-448. doi: 10.1016/j.hrtlng.2020.04.014. Epub 2020 Apr 23.
本文引用的文献
1
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.血管紧张素转换酶 2 的器官保护作用及其对 COVID-19 预后的影响。
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.
2
Are certain drugs associated with enhanced mortality in COVID-19?某些药物是否与新冠病毒疾病（COVID-19）死亡率升高有关？
QJM. 2020 Jul 1;113(7):509-510. doi: 10.1093/qjmed/hcaa103.
3
COVID-19 and Cardiovascular Disease.新型冠状病毒肺炎与心血管疾病。
Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.
4
COVID-19 and the cardiovascular system.新型冠状病毒肺炎与心血管系统。
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
5
Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.新型冠状病毒（2019-nCoV/SARS-CoV-2）受体ACE2在不同人群中的比较遗传分析。
Cell Discov. 2020 Feb 24;6:11. doi: 10.1038/s41421-020-0147-1. eCollection 2020.
6
Coronavirus disease-2019: An update on third coronavirus outbreak of 21st century.2019冠状病毒病：21世纪第三次冠状病毒疫情最新情况
QJM. 2020 May 1;113(5):384-386. doi: 10.1093/qjmed/hcaa081.
Zotero 插件